
    
      This is a randomized, multi-center, double-blind, placebo-controlled phase III trial of
      Orantinib administered in combination with TACE in patients with unresectable HCC.

      Patients will be randomly assigned (1:1) to receive TACE given in combination with either
      Orantinib (200 mg orally, twice per day) or placebo.

      ORIENTAL:ORantinib InvEstigatioN on TAce combination triaL.
    
  